The World Health Organization (WHO) and Gavi, the Vaccine Alliance, have invited developing countries like Ghana, Kenya, and Malawi to apply for funding to access the RTS,S malaria vaccine.
International support worth $160m from 2022 to 2025 will be made available to the aforementioned countries, which piloted the jab in 2019.
Other countries which are affected by malaria can apply for the funding from September.
It is thought one child dies from malaria each minute in Africa.
The WHO recommended the widespread use of the RTS,S vaccine in October 2021, which has led to more countries expressing an interest in it.
But the jab only provides 30% protection.
To date, about 1.3 million children have received at least one of the required four doses of the vaccine since it was piloted in 2019.
However, the supply remains limited in the continent.
Africa needs at least 80 to 100 million doses annually, according to the WHO.
The manufacturer GSK says it can only produce about 15 million doses every year until 2028.
“The work towards a malaria vaccine has been long and hard,” said Gavi CEO Dr Seth Berkley. “Today we begin a new chapter: alongside existing interventions, this new tool will allow us to save more lives in countries hit hardest by this killer disease.”
The introduction of the RTS,S/AS01 malaria vaccine builds on successful implementation pilots and will be the first ever widespread malaria vaccination programme. Alongside currently recommended malaria control interventions